Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.
about
ZnO nanoparticles enhanced antibacterial activity of ciprofloxacin against Staphylococcus aureus and Escherichia coliSustained Antibiotic-Eluting Intra-Ocular Lenses: A New ApproachMaintaining fluoroquinolone class efficacy: review of influencing factors.Studies on the antimicrobial properties of N-acylated ciprofloxacins.Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in CanadaDual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniaeFluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.Overcoming antimicrobial resistance by targeting resistance mechanisms.Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity.Piperine, a phytochemical potentiator of ciprofloxacin against Staphylococcus aureusAntimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance.Contribution of the 8-methoxy group to the activity of gatifloxacin against type II topoisomerases of Streptococcus pneumoniae.Activity of and resistance to moxifloxacin in Staphylococcus aureus.Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.Levofloxacin: update and perspectives on one of the original 'respiratory quinolones'.Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes.Moxifloxacin modifies corneal fibroblast-to-myofibroblast differentiationEvaluation of Moxifloxacin-induced Biochemical Changes in MiceRapid eradication of Listeria monocytogenes by moxifloxacin in a murine model of central nervous system listeriosisA brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP).Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae.Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones.10 years' experience with the pneumococcal quinolone moxifloxacin.Role of pentoxifylline and sparfloxacin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic patients.Gemifloxacin: a new fluoroquinolone.New treatments for bacterial keratitis.The use of moxifloxacin for acute exacerbations of chronic obstructive pulmonary disease and chronic bronchitis.Antibacterial Activity of Ciprofloxacin-Encapsulated Cockle Shells Calcium Carbonate (Aragonite) Nanoparticles and Its Biocompatability in Macrophage J774A.1.Fluoroquinolone resistance is a poor surrogate marker for type II topoisomerase mutations in clinical isolates of Streptococcus pneumoniae.Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniaeSelection and genetic characterization of Streptococcus pneumoniae mutants resistant to the des-F(6) quinolone BMS-284756.Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.Functional characterisation of mycobacterial DNA gyrase: an efficient decatenase.Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in target specificity.Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
P2860
Q28275835-96E54E8F-752D-4549-9FB0-56D2F73BB362Q28552701-12BA73C2-613A-410E-99D6-C9B59171809BQ30310427-0A05E466-05FE-4EA1-8668-39A84957E3B1Q31096940-C3D89F55-60F8-4EB0-A9D7-E7B83B7EED9AQ33663032-1B8127F8-4C86-4322-92AD-0DF4DF2C283AQ33770013-6DA9DE1C-8D90-4BFF-B904-726FFB73D9AFQ33981343-05C33846-034C-4D88-ABE8-592EA3F17E40Q33982417-A250E863-9E01-4349-94AF-4339F7E6661DQ34113933-00D83669-8803-4D47-BDD6-D057812A4FCCQ34211132-BA4AB37A-8513-41AB-AF68-FABA646497E5Q34347885-D4B60AD4-A956-40A2-8A5F-CEDCF5C8B11BQ34352260-1F2D46FA-E39B-4198-8954-B8E417389639Q34502866-CFAAF77D-79BE-419C-828A-73FD91CBAA84Q34721556-BF7747C5-17AB-4DCB-B017-DC0EBA4BE4E0Q34885313-8A377C50-A2E5-4319-8D6F-BD24815A5F09Q35798789-2D43EA79-E75B-4B95-9B44-C74523069E91Q35917230-40CBB8D4-2DE6-41C0-A85E-E53346E58AA0Q36492180-2D9F607D-0CB3-474E-B2D9-98DC1291A9BAQ36593797-4E9662C2-04AC-4790-8A84-3A78A8B34FCCQ36681754-3386E988-B115-4CAD-A54C-F6ABFB040649Q36865298-713D14BF-AF8D-4A31-9F16-72C1ACEDF23CQ36870838-462B6C56-A5E2-499A-9183-9A3CE9E7B010Q37017387-10076217-1CD6-4338-AE58-1A541A96FC27Q37120372-8C1B9624-EF0F-4AD9-B5C2-3FE03611EBA9Q37191156-9EEE28A5-DC96-4049-B823-74676714F7A3Q37579919-B82D9899-D793-43D8-9FAB-3B38095E2377Q37657448-594529C7-4A7C-410F-9FF9-3D0632DD932FQ37867123-AE0DF20B-F82B-43BC-98BC-D80538F27D4CQ38044726-1BBE80EE-8FA1-4286-8FA4-236AB1E3ACFBQ38056764-E1B302B5-E143-4546-AE23-BC88EEC1806AQ38769189-5E382453-2B08-4B27-A669-04F0D205EA20Q39465570-7AEC19E6-F694-4E88-BF07-DB4BC20F9857Q39477371-D278467F-16FE-44DB-9932-FF546233E274Q39478343-14434275-1D89-450E-879B-BF1D3E7A20FDQ39478563-65588C9A-E65D-495D-B795-28F2D98C5963Q39478835-22647CA5-5528-4860-AEA8-CF5C991C0F2FQ39607881-12C13C00-74DC-4079-8999-428F2EC92911Q39651272-3EEBAF64-8F5F-4E6B-95F9-7E3BEDEDCCE5Q39651301-929821C0-FFF9-4AEE-B5E2-638236553CA5Q39651324-E7421528-A3AF-4F43-B41E-D3E021814567
P2860
Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.
@ast
Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.
@en
type
label
Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.
@ast
Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.
@en
prefLabel
Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.
@ast
Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.
@en
P2093
P356
P1476
Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.
@en
P2093
G A Noskin
J J Millichap
L R Peterson
P304
P356
10.1093/JAC/45.5.583
P407
P577
2000-05-01T00:00:00Z